Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma

Lorenzo Bello, Valeria Lucini, Francesco Costa, Mauro Pluderi, Carlo Giussani, Francesco Acerbi, Giorgio Carrabba, Marilou Pannacci, Dario Caronzolo, Silvia Grosso, Svetlana Shinkaruk, Federica Colleoni, Xavier Canron, Giustino Tomei, Gerard Deleris, Andreas Bikfalvi

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: We investigated the ability of the combinatorial administration of different inhibitors with activities on glioma angiogenesis, migration, and proliferation to produce a prolonged inhibition of glioma growth. Experimental Design: We combined inhibitors affecting solely tumor angiogenesis (PF-4/CTF, cyclo-VEGI) or inhibitors affecting both angiogenesis and invasion together (PEX, PF-4/DLR). Results: When administered in combination, these drugs produced a prolonged and increased inhibition of glioma growth independently from the type of inhibitor used. The combinatory administration was more effective than the administration of a single inhibitor alone, and a strong therapeutic response was reached with a significantly lower amount of protein. The strongest inhibition was observed when human PEX and PF-4/DLR, which affect both glioma angiogenesis and invasion by separate mechanisms, were combined. Conclusions: This supports the concept that prolonged glioma growth inhibition can be achieved by simultaneous delivery of molecules that target both tumor and endothelial cells and acting by separate mechanisms.

Original languageEnglish
Pages (from-to)4527-4537
Number of pages11
JournalClinical Cancer Research
Volume10
Issue number13
DOIs
Publication statusPublished - Jul 1 2004

Fingerprint

Glioma
Therapeutics
Growth Inhibitors
Drug Combinations
Growth
Neoplasms
Research Design
Endothelial Cells
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. / Bello, Lorenzo; Lucini, Valeria; Costa, Francesco; Pluderi, Mauro; Giussani, Carlo; Acerbi, Francesco; Carrabba, Giorgio; Pannacci, Marilou; Caronzolo, Dario; Grosso, Silvia; Shinkaruk, Svetlana; Colleoni, Federica; Canron, Xavier; Tomei, Giustino; Deleris, Gerard; Bikfalvi, Andreas.

In: Clinical Cancer Research, Vol. 10, No. 13, 01.07.2004, p. 4527-4537.

Research output: Contribution to journalArticle

Bello, Lorenzo ; Lucini, Valeria ; Costa, Francesco ; Pluderi, Mauro ; Giussani, Carlo ; Acerbi, Francesco ; Carrabba, Giorgio ; Pannacci, Marilou ; Caronzolo, Dario ; Grosso, Silvia ; Shinkaruk, Svetlana ; Colleoni, Federica ; Canron, Xavier ; Tomei, Giustino ; Deleris, Gerard ; Bikfalvi, Andreas. / Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 13. pp. 4527-4537.
@article{10c505887d6945e9ab4507af0ca77b3e,
title = "Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma",
abstract = "Purpose: We investigated the ability of the combinatorial administration of different inhibitors with activities on glioma angiogenesis, migration, and proliferation to produce a prolonged inhibition of glioma growth. Experimental Design: We combined inhibitors affecting solely tumor angiogenesis (PF-4/CTF, cyclo-VEGI) or inhibitors affecting both angiogenesis and invasion together (PEX, PF-4/DLR). Results: When administered in combination, these drugs produced a prolonged and increased inhibition of glioma growth independently from the type of inhibitor used. The combinatory administration was more effective than the administration of a single inhibitor alone, and a strong therapeutic response was reached with a significantly lower amount of protein. The strongest inhibition was observed when human PEX and PF-4/DLR, which affect both glioma angiogenesis and invasion by separate mechanisms, were combined. Conclusions: This supports the concept that prolonged glioma growth inhibition can be achieved by simultaneous delivery of molecules that target both tumor and endothelial cells and acting by separate mechanisms.",
author = "Lorenzo Bello and Valeria Lucini and Francesco Costa and Mauro Pluderi and Carlo Giussani and Francesco Acerbi and Giorgio Carrabba and Marilou Pannacci and Dario Caronzolo and Silvia Grosso and Svetlana Shinkaruk and Federica Colleoni and Xavier Canron and Giustino Tomei and Gerard Deleris and Andreas Bikfalvi",
year = "2004",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-04-0194",
language = "English",
volume = "10",
pages = "4527--4537",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma

AU - Bello, Lorenzo

AU - Lucini, Valeria

AU - Costa, Francesco

AU - Pluderi, Mauro

AU - Giussani, Carlo

AU - Acerbi, Francesco

AU - Carrabba, Giorgio

AU - Pannacci, Marilou

AU - Caronzolo, Dario

AU - Grosso, Silvia

AU - Shinkaruk, Svetlana

AU - Colleoni, Federica

AU - Canron, Xavier

AU - Tomei, Giustino

AU - Deleris, Gerard

AU - Bikfalvi, Andreas

PY - 2004/7/1

Y1 - 2004/7/1

N2 - Purpose: We investigated the ability of the combinatorial administration of different inhibitors with activities on glioma angiogenesis, migration, and proliferation to produce a prolonged inhibition of glioma growth. Experimental Design: We combined inhibitors affecting solely tumor angiogenesis (PF-4/CTF, cyclo-VEGI) or inhibitors affecting both angiogenesis and invasion together (PEX, PF-4/DLR). Results: When administered in combination, these drugs produced a prolonged and increased inhibition of glioma growth independently from the type of inhibitor used. The combinatory administration was more effective than the administration of a single inhibitor alone, and a strong therapeutic response was reached with a significantly lower amount of protein. The strongest inhibition was observed when human PEX and PF-4/DLR, which affect both glioma angiogenesis and invasion by separate mechanisms, were combined. Conclusions: This supports the concept that prolonged glioma growth inhibition can be achieved by simultaneous delivery of molecules that target both tumor and endothelial cells and acting by separate mechanisms.

AB - Purpose: We investigated the ability of the combinatorial administration of different inhibitors with activities on glioma angiogenesis, migration, and proliferation to produce a prolonged inhibition of glioma growth. Experimental Design: We combined inhibitors affecting solely tumor angiogenesis (PF-4/CTF, cyclo-VEGI) or inhibitors affecting both angiogenesis and invasion together (PEX, PF-4/DLR). Results: When administered in combination, these drugs produced a prolonged and increased inhibition of glioma growth independently from the type of inhibitor used. The combinatory administration was more effective than the administration of a single inhibitor alone, and a strong therapeutic response was reached with a significantly lower amount of protein. The strongest inhibition was observed when human PEX and PF-4/DLR, which affect both glioma angiogenesis and invasion by separate mechanisms, were combined. Conclusions: This supports the concept that prolonged glioma growth inhibition can be achieved by simultaneous delivery of molecules that target both tumor and endothelial cells and acting by separate mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=3042815043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042815043&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0194

DO - 10.1158/1078-0432.CCR-04-0194

M3 - Article

VL - 10

SP - 4527

EP - 4537

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -